Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

er unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K and its other reports filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

FINANCIAL TABLES FOLLOWCEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended March 31, 20132012Sales:System and other sales

$
,010$
5,230Reagent and disposable sales

75,92862,062Total sales

91,93877,292Costs and operating expenses:Cost of sales 

42,89235,608Collaboration profit sharing 

2,1101,684Research and development

17,72722,102Sales and marketing

19,12614,512General and administrative

9,76311,051Total costs and operating expenses 

91,61884,957Income (loss) from operations 

320(7,665)Other income, net

374238Income (loss) before income taxes

694(7,427)Benefit from (provision for) income taxes

(381)1,901Net income (loss)

$
313$
(5,526)Basic net income (
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
2. Cepheid Announces Board of Directors Changes
3. Cepheid Reports 2012 Second Quarter Results
4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. Cepheid Welcomes Senior Vice President of Human Resources
11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... Aug. 3, 2011 Neuralstem, Inc. (NYSE Amex: ... of Defense (DOD) contract to develop its human neural ... tumors. The research contract, entitled "Research to Treat Cancerous ... out in collaboration with Principal Investigator John Zhang, MD, ...
... 2011 Cambrex Corporation (NYSE: CBM ) reports second ... Highlights Reported sales increased by ... compared to the second quarter of 2010. EBITDA was $13.2 ... compared to $12.1 million in the second quarter of 2010. ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ... on Monday, August 8, 2011, after the U.S. financial markets ... webcast on Monday, August 8, 2011, at 5:00 p.m. Eastern ... and highlights.  A live webcast of the call will be ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Cambrex Reports Second Quarter of 2011 Results 2Cambrex Reports Second Quarter of 2011 Results 3Cambrex Reports Second Quarter of 2011 Results 4Cambrex Reports Second Quarter of 2011 Results 5Cambrex Reports Second Quarter of 2011 Results 6Cambrex Reports Second Quarter of 2011 Results 7Cambrex Reports Second Quarter of 2011 Results 8Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2
(Date:10/22/2014)... DENVER , Oct. 20, 2014  Leading identity ... years time half of the world,s population will have ... in Europe . Asia ... dominate the market accounting for more than 60% of ... Acuity,s report  -- "The Global National ...
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... Troy, N.Y. Engineering researchers at Rensselaer Polytechnic Institute ... diverse areas to help create a closed-loop artificial pancreas. ... administer insulin to patients with Type 1 diabetes, and ... living with the chronic disease. For six years, ...
... A study conducted by VTT Technical Research Centre of Finland ... grades 95E10 and 98E5 sold in Finland as regards fuel ... tests conducted by VTT using six used cars of different ... claimed in public that fuel consumption is significantly higher with ...
... a low-cost healthy lifestyle program, including self-weighing weekly or ... them from gaining too much weight during early pregnancy. ... Endocrine Society,s 93rd Annual Meeting in Boston. "Preventing ... health of all mothers and their babies and can ...
Cached Biology News:Engineering new weapons in the fight against juvenile diabetes 2Engineering new weapons in the fight against juvenile diabetes 3VTT: No significant difference in car fuel consumption between E10 and E5 petrol grades 2Pregnant women can prevent excess weight gain with simple steps, study finds 2
... a concentrated formulation of a rinsing buffer ... technology, as well as for manual immunostaining. ... Brigati M.D., Department of Pathology, University of ... recommended for all the rinsing steps performed ...
... MALDI O-TOF creates a new category for ... platform that has been licensed to the ... Manitoba. , As the first single MALDI-TOF ... collisional cooling, the prOTOF 2000 represents a ...
... miVac DNA is an ideal small concentrator ... concentrator capable of removing water and organic ... including tubes, microplates, vials and round bottom ... for the busy lab. ,The built-in special ...
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
Biology Products: